Longeveron LGVN 深 滬
已收盤 09-19 16:00:00 美东时间
2.06
+0.010
+0.49%
華盛通- 最 高2.24
- 今 開2.09
- 成交量 61.71万股
- 最 低 2.03
- 昨 收 2.05
- 總市值 517.78万
- 52周最高 26.70
- 市盈率 靜 --
- 換手率 24.55%
- 52周最低 0.7707
- 委 比 22.78%
- 總股本 251.35万
- 歷史最高 450.00
- 量 比 1.52
- 振 幅 10.24%
- 歷史最低 2.03
- 每 手 1
- 風險率 7.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多快讯 | Longeveron公司：Maxim Group将目标价从15美元下调至6美元
Longeveron Inc : Maxim Group Cuts Target Price to $6 From $15
08-27 12:10
Longeveron reports Q2 results
Longeveron press release (NASDAQ:LGVN): Q2 GAAP EPS of -$1.83. Revenue of $468K (vs. $217K in 2Q23). Cash and cash equivalents and marketable securities as of June 30, 2024 were $12.4M. The company be...
08-15 22:54
Longeveron Q2 2024 GAAP EPS $(1.83) Up From $(2.67) YoY, Sales $468.00K Miss $525.00K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(1.83) per share. This is a 31.46 percent increase over losses of $(2.67) per share from the same period last year. The company reported quarterly sales of $468.00
08-15 04:22
快讯 | Longeveron宣布2024年第二季度财务业绩并提供业务更新
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Busine...
08-15 04:05
AD研发潮再起？一天两笔合作，近35亿美元流向神经退行性疾病领域
21世纪经济报道记者 韩利明 上海报道 同一天内，神经退行性疾病迎来两笔巨额交易，阿尔茨海默病（AD）领域的研发热潮或再被“引爆”。...
08-08 20:31
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.
08-02 06:55
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
Cognition Therapeutics' Phase 2 'SHINE' study shows CT1812 leads to cognitive improvement in Alzheimer's patients over six months. Participants showed better performance on cognitive and functional measures compared to placebo.
07-29 23:31
Market-Moving News for July 29th
LGVN: 49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease; Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk
07-29 20:22
HC Wainwright & Co. Maintains Buy on Longeveron, Lowers Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $12 to $10.
07-29 18:19
